The results suggest Ozempic could potentially become a new alternative treatment for opioid use disorder, which could help ...

Weight-loss drugs sell in Europe for a fraction of what they cost in the United States, a pattern that is typical for ...

Novo Nordisk CEO grilled over company's pricing for the diabetes drug Ozempic and the weight-loss drug Wegovy.

Novo Nordisk CEO explains decision to discontinue the long-acting insulin Levemir. He blamed pharmacy managers and health ...

Novo Nordisk under political pressure over high U.S. drug prices as CEO testifies before Congress. PBMs and limited impact on ...

The CEO of Novo Nordisk wouldn’t commit to lowering the prices of Ozempic and Wegovy during a Senate hearing Tuesday, despite ...

During a tense hearing before a Senate committee on Tuesday, Novo Nordisk CEO Lars Fruergaard Jørgensen faced toug ...

CEO Lars Fruergaard Jørgensen was grilled by a U.S. Senate committee, Cantor Fitzgerald Managing Director Louise Chen noted ...

CEO Lars Fruergaard Jørgensen agreed today, during a Senate committee hearing, to sit down with lawmakers and pharmacy ...

Novo Nordisk CEO Lars Fruergaard Jørgensen testified before the Senate Health, Education, Labor and Pension committee on ...

Novo Nordisk has been criticised by US politicians for the high pricing of its popular weight-loss and diabetes drugs. But ...

Analyst Evan Seigerman of BMO Capital maintained a Buy rating on Novo Nordisk (NVO – Research Report), retaining the price target of ...